# A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

> **NCT06894459** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 180 (estimated)

## Conditions studied

- Head and Neck Cancers

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT06894459
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06894459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06894459, "A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06894459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*